Biogen gains $20B in value on new hope for Alzheimer's drug
November 04, 2020 at 11:47 AM EST
FDA advisors say in documents released Wednesday that they find Biogen's drug data “robust and exceptionally persuasive.”
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|